Status:
COMPLETED
High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma
Lead Sponsor:
Nantes University Hospital
Collaborating Sponsors:
French Innovative Leukemia Organisation
Hoffmann-La Roche
Conditions:
B-Cell Lymphoma
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
A prospective pilot trial was proposed to patients with DLBCL, with IH or high adjusted IPI, up to the age of 60 y.o. This program consisted of 2 courses of high-dose R-CHOP-like regimen, followed by ...
Detailed Description
Superiority of HDT with autologous stem cell transplantation (ASCT) in the upfront treatment of poor-risk DLBCL remains an option for intermediate-high (IH) or high IPI young adults. We updated result...
Eligibility Criteria
Inclusion
- Age 18 to 60 y.o
- Aggressive Large B-Cell Lymphoma (CD20+)
- Ann Arbor stage III, IV
- IH or high adjusted IPI
- signed inform consent
Exclusion
- Age \< 18 ou \> 60 y.o
- other type of lymphoma
- serology VIH +
- other neoplasms apart from basal cell carcinoma or situ carcinoma
Key Trial Info
Start Date :
April 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00965289
Start Date
April 1 2002
End Date
June 1 2009
Last Update
August 26 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Nantes, France, 44000